Become A Featured Company

Psychedelics, the Next Frontier in Drug Research

Ryan Allway

March 1st, 2020

App, Exclusive, News, Top News

A big factor in the recent rise of cannabis legalization is the emergence of legitimate scientific research into the potential health benefits of the plant’s active ingredients, called cannabinoids. Medicines are often derived from naturally occurring compounds, from aspirin to insulin to penicillin. A decent body of research is currently pointing to psilocybin, the psychedelic active ingredient in some types of mushrooms, as well as other psychedelics like LSD, as the next big natural drug discovery. Researchers are in various stages of studying the effect of psychedelics on conditions ranging from depression to addiction to migraines to anxiety and more. It might be time to pay attention to the field as more researchers test the therapeutic potential of psychedelics.

One company certainly paying attention is EHave, Inc. (OTC: EHVVF). The company has developed a technology platform that helps doctors and patients make data-informed treatment decisions for a variety of mental health indications. With the formation of a subsidiary called Mycotopia Therapy and an initial acquisition of PsychedeliTech, the company is becoming a major player in the emerging psychedelic medicine space. The Ehave Dash, already HIPAA and GDPR compliant, will be used as a central clearinghouse for psychedelic research data and clinical trial tracking with the intent to further advance the science of psychedelic therapies.

Psychedelic Research Enters the Mainstream

Just last year, the Johns Hopkins School of Medicine opened the Center for Psychedelic and Consciousness Research in Baltimore. Headed by renowned researcher Roland R. Griffiths, Ph.D., the Center aims to further research the school has already been conducting. Initial areas of focus include potential therapies for opioid addiction, Alzheimer’s disease, PTSD, and anorexia among other conditions. Johns Hopkins researchers have been pioneers in the field as the first researchers, in 2000, to get US regulatory approval for the use of psychedelics in health volunteers. Since then, the school’s researchers have published more than 60 peer-reviewed studies and demonstrated safe practices for psychedelic research that have set the standard for other studies across the world.

There are plenty of other researchers pursuing potential psychedelic therapies. The University of Toronto Mississauga recently started a Psychedelic Studies Research Program. The British Columbia Centre on Substance Abuse is launching a Phase III clinical trial of MDMA as a treatment for PTSD, in conjunction with 16 other locations throughout North America and Israel, and funded by the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS). The MAPS site has comprehensive lists of research, both ongoing and completed, conducted by MAPS as well as other organizations. There is a lot of scientific interest in psychedelics, and it is growing exponentially.

EHave’s Plan

The PsychedeliTech acquisition is just the first step for EHave in a comprehensive plan to bring together the diverse and scattered research (and researchers) into one collaborative platform. PsychedeliTech is hosting the inaugural PsyTech Summit March 29-30, in Tel Aviv, Israel. Modeled after the hugely successful CannaTech conference, a global gathering for the cannabis industry. In fact, PsychedeliTech is a subsidiary of Israel Cannabis Limited (iCAN), the creator of the CannaTech conference, and the two conferences run back-to-back at the same location this year. 

The goal of the PsyTech Summit is to elevate the psychedelics conversation, foster normalization, and accelerate innovation. Why is EHave acquiring the company and the conference? Because its subsidiary, Mycotopia Therapy, was founded to work toward the same goals. EHave believes its EHave Dash platform can play a crucial role in the worldwide advancement of psychedelic research. The Dash is HIPAA and GDPR compliant, meaning that the data carried by the Dash is totally secure and in line with the world’s most strict privacy and security rules. The idea is to compile all psychedelic research and results in the EHave Dash, providing valuable and easily accessible information for scientists across the globe as they pursue their own studies.

The PsyTech Summit is a perfect vehicle for fostering crucial relationships with innovators in the space. It could also serve to introduce Mycotopia Therapy to other potential investments or acquisitions that fit under the company’s mission, as the PsyTech acquisition is just the first of many moves to come.

The Upshot

The story of psychedelics as therapeutic treatments is now unfolding across the world. There is a lot of promising research into a wide variety of problematic neurological and psychological conditions that have resisted more traditional treatments to date. It’s a potentially explosive industry in its infancy, and EHave is making moves to become a key cog in the industry’s development. Keep an eye out here for more news regarding both the company and the movement in general.

Please click here for additional Information on EHave, Inc. (OTC: EHVVF)

Please click here for additional Information on Mycotopia Therapy

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading